基于FAERS对靶向HER2抗体偶联药品不良反应/事件的分析

doi:10.19803/j.1672-8629.20220658

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (8): 915-920.
DOI: 10.19803/j.1672-8629.20220658

基于FAERS对靶向HER2抗体偶联药品不良反应/事件的分析

何雄¹, 马俊龙², 阳国平^2,*

¹湖南省药品审评与不良反应监测中心,湖南长沙 410013;
²中南大学湘雅三医院临床药理中心,湖南长沙 410013

收稿日期:2022-11-17 出版日期:2023-08-15 发布日期:2023-08-07
通讯作者: ^*阳国平,男,博士,教授·博导,临床药理学研究。E-mail: ygp9880@126.com
作者简介:何雄,女,本科,副主任药师,药品技术审评和检查。
基金资助:
湖南省科技重点专项（2020SK2010）

Adverse events caused by HER2 conjugated antibodies via FAERS

HE Xiong¹, MA Junlong², YANG Guoping^2,*

¹Hunan Center for Drug Evaluation and ADR Monitoring, Changsha Hunan 410013, China;
²Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha Hunan 410013, China

Received:2022-11-17 Online:2023-08-15 Published:2023-08-07

摘要/Abstract

摘要： 目的基于美国食品药品监督管理局不良事件报告系统（FAERS）,对靶向HER2的抗体偶联药品T-DM1和T-DXd进行药品不良反应/事件（ADR/ADE）信号挖掘分析,为临床安全用药提供参考。方法从FAERS提取2020年1月1日至2022年6月30日的药物ADR/ADE报告,合并去除重复报告,并对ADR/ADE信号进行筛选分析。结果获得以T-DM1或T-DXd为首要怀疑药物的ADR/ADE报告共2 806例,筛选后得到ADR/ADE信号3 979个。对ADR/ADE信号分类发现,2种药ADR/ADE累及系统-器官分类（SOC）基本相同,T-DM1还累及生殖系统及乳腺疾病以及血管类疾病。T-DM1所关联的ADR/ADE信号强度较高的有肝肺综合征、蜘蛛痣和结节状再生性增生,T-DXd则为kL-6升高、癌性淋巴管炎和间质性肺疾病。在报告信号强度前20位的ADR/ADE中,T-DM1药品说明书中未提及的有蜘蛛痣、感觉减退和感觉异常,T-DXd有角膜炎和股骨颈骨折。结论挖掘的真实世界ADR/ADE报告与说明书中记载一致,还报告了新的ADR/ADE,为T-DM1和T-DXd的临床使用提供参考。

关键词: 恩美曲妥珠单抗, 德喜曲妥珠单抗, 人表皮生长因子受体-2, 抗体偶联药物, 肿瘤, 乳腺癌, 美国食品药品监督管理局不良事件报告系统, 药品不良反应/事件

Abstract: Objective To provide reference for clinical drug safety by mining and analyzing adverse drug reaction/event (ADR/ADE) signals of T-DM1 and T-DXd which are antibody-conjugated drugs targeting HER2. Methods ADR/ADE reports submitted between January 1, 2020 and June 30, 2022 were retrieved from the Adverse Event Reporting System of the United States Food and Drug Administration (FAERS) before signals were screened and analyzed after removal of duplicate reports. Results A total of 2 806 ADR/ADE reports were collected with T-DM1 or T-DXd as the primary suspected drug, and 3 979 ADR/ADE signals were obtained after screening. The classification of ADR/ADE signals found that the signals of the two drugs were of a similar system organ class (SOC). However, T-DM1 was additionally involved in the reproductive system and breast disorders and vascular disorders. Furthermore, ADR/ADE signal intensities associated with T-DM1 were higher for hepatopulmonary syndrome, sideroblastic nevus and nodular aplastic hyperplasia, while T-DXd was more significantly correlated with elevated kL-6, carcinomatous lymphadenopathy and interstitial lung diseases. Among the top 20 ADR/ADE in terms of signal intensities, spider naevus, hyperalgesia and sensory abnormality were not mentioned in the instructions of T-DM1, while keratitis and femoral neck fracture were not mentioned in T-DXd instructions. Conclusion The real-world ADR/ADE mined conform with those specified in drug instructions. New ADR/ADE are also reported that can provide reference for clinical use of T-DM1 and T-DXd.

Key words: T-DM1, T-DXd, HER2, ADC, tumor, breast cancer, FAERS, ADR/ADE

中图分类号:

何雄, 马俊龙, 阳国平. 基于FAERS对靶向HER2抗体偶联药品不良反应/事件的分析[J]. 中国药物警戒, 2023, 20(8): 915-920.

HE Xiong, MA Junlong, YANG Guoping. Adverse events caused by HER2 conjugated antibodies via FAERS[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 915-920.

参考文献

[1] GERSON JN, SKARIAH S, DENLINGER CS, et al.Perspectives of HER2-targeting in gastric and esophageal cancer[J]. Expert Opin Investig Drugs, 2017, 26(5): 531-540.
[2] BALLANTYNE A, DHILLON S.Trastuzumab emtansine: first global approval[J]. Drugs, 2013, 73(7): 755-765.
[3] LEWIS PHILLIPS GD, LI G, DUGGER DL, et al.Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate[J]. Cancer Res, 2008, 68(22): 9280-9290.
[4] VERMA S, MILES D, GIANNI L, et al.Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2012, 367(19): 1783-1791.
[5] KEAM SJ.Trastuzumab deruxtecan: first approval[J]. Drugs, 2020, 80(5): 501-508.
[6] CORTÉS J, KIM SB, CHUNG WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer[J]. N Engl J Med, 2022, 386(12): 1143-1154.
[7] HU Y, GONG J, ZHANG L, et al.Colitis following the use of immune checkpoint inhibitors: a real-world analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System[J]. Int Immunopharmacol, 2020, 84: 106601.
[8] CHEN L, WU BH, YAN K.Disproportional method applied in ADR signal mining of bevacizumab[J]. Central South Pharmacy(中南药学). 2018, 16(2): 174-178.
[9] LI YF,WANG AN,FENG X.A real-world study leveraging US Food and Drug Administration Adverse Events Reporting System of olaparib[J]. Chinese Pharmaceutical Journal(中国药学杂志). 2021, 56(20): 1631-1636.
[10] LINDQUIST M, STÅHL M, BATE A, et al. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database[J]. Drug Saf, 2000, 23(6): 533-542.
[11] WU B, HU Q, TIAN F, et al.A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA Adverse Event Reporting System data[J]. Sci Rep, 2021, 11(1): 10709.
[12] ZHANG QL, DING YF, CHEN L, et al.Analysis of the adverse events of pembrolizumab and nivolumab based on FAERS[J]. China Pharmacist(中国药师), 2022, 25(8): 1384-1390.
[13] OGITANI Y, AIDA T, HAGIHARA K, et al.DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1[J]. Clin Cancer Res, 2016, 22(20): 5097-5108.
[14] YANG J, YANG Y, WU B, et al.Data mining of antibody-drug conjugate related adverse events of peripheral neuropathy based on FAERS[J]. Herald of Medicine(医药导报), 2022, 41(7): 958-963.
[15] WU ZY, HE N, CHENG YC, et al.Data mining of adverse drug reaction signals for ado-trastuzumab emtansine and brentuximab vedotin based on FAERS database[J]. China Pharmacy(中国药房), 2022, 33(6): 740-744.
[16] Hospital Pharmacy Committee of Chinese Pharmaceutical Association, Tumor Clinical Chemotherapy Committee of China Anti-cancer Association. Interdisciplinary management of the safety associated with antibody-drug conjugates: chinese expert panel consensus[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2023, 43(1): 1-13.
[17] KUKSIS M, GAO Y, TRAN W, et al.The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis[J]. Neuro Oncol, 2021, 23(6): 894-904.
[18] ORLANDI A, FASCIANI R, CASSANO A, et al.Trastuzumab-induced corneal ulceration: successful no-drug treatment of a “blind” side effect in a case report[J]. BMC Cancer, 2015, 15: 973.

基于FAERS对靶向HER2抗体偶联药品不良反应/事件的分析

Adverse events caused by HER2 conjugated antibodies via FAERS

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[2]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[3]	辛灵怡, 杨洋, 朱婧, 何娜, 张静媚, 王航天, 陈琴华, 杨光义. 重楼抗肿瘤活性成分分类及作用机制研究进展[J]. 中国药物警戒, 2024, 21(2): 235-240.
[4]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[5]	张亮亮, 胡昌坤, 吴泽坤, 周维, 廖泽彬, 高月. 富马酸二甲酯对肠道辐射损伤防护作用及机制研究[J]. 中国药物警戒, 2024, 21(1): 83-88.
[6]	熊玮仪, 任经天. 抗肿瘤药说明书安全性信息上市后修订的考虑要点[J]. 中国药物警戒, 2024, 21(1): 94-97.
[7]	张立, 汪余嘉, 张玲玲, 陈家鑫, 林敏华, 林小惠, 聂雪坤. 真实世界免疫检查点抑制剂相关不良反应监测数据分析[J]. 中国药物警戒, 2023, 20(9): 1035-1038.
[8]	张夏兰, 袁静, 吴斌, 秦媛媛. 甲磺酸阿帕替尼在恶性肿瘤患者的用药特征分析[J]. 中国药物警戒, 2023, 20(8): 927-932.
[9]	严亦舒, 赵岩, 卢天公, 孙震晓. 大黄素-8-O-β-D-葡萄糖苷联合紫杉醇抑制人乳腺癌细胞活力及侵袭转移的研究[J]. 中国药物警戒, 2023, 20(7): 728-734.
[10]	孟康康, 刘赛月. 辅酶Q10注射剂上市后安全性分析[J]. 中国药物警戒, 2023, 20(7): 795-798.
[11]	郑轶, 罗枭, 张朋朋, 刘永梅, 叶小飞, 郭晓晶, 陈霞, 贺佳. 基于主动监测系统的免疫检查点抑制剂心肌炎不良反应探索[J]. 中国药物警戒, 2023, 20(6): 634-638.
[12]	辛雨濛, 卢天公, 孙震晓. 甘草干姜汤对顺铂所致巨噬细胞毒性的保护作用[J]. 中国药物警戒, 2023, 20(6): 661-670.
[13]	赵稳华, 舒鹤, 倪晨明, 郭晋敏. 基于FAERS数据库的氨吡啶缓释片不良反应信号挖掘分析[J]. 中国药物警戒, 2023, 20(6): 684-690.
[14]	. 国家药品不良反应监测年度报告（2022年）[J]. 中国药物警戒, 2023, 20(6): 712-719.
[15]	李容容, 李盟, 苟悦, 罗琼, 吕桦, 孙鑫, 刘成海. 113例抗肿瘤药物相关肝损伤的临床特点及危险因素分析[J]. 中国药物警戒, 2023, 20(5): 505-510.